A panel of European Medicines Agency recommended against granting marketing approval to Portola Pharmaceuticals Inc.’s oral blood thinner, saying the benefits of the drug did not outweigh risks.

A European Medicines Agency panel recommended against approving Puma Biotechnology’s lead breast cancer drug, an outcome the U.S drugmaker signaled in January 2018.